• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Global Over-the-Counter (OTC) Drug Markets

$3,995.00 – $7,990.00

Clear
SKU: KLI15581138 Categories: Over-the-Counter (OTC) Drugs, Pharmaceuticals Market Research Pages: 171
  • Description
  • Table of Contents
  • Latest reports

Description

Global Over-the-Counter (OTC) Drug Markets

Global Over-the-Counter (OTC) Drug Markets discusses the world and regional OTC markets, including information on the following: world OTC drug market revenues: 2017 to 2023; top twenty OTC drug markets, country market share (%), 2017 (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia, rest of world); and world OTC drug market revenues, markets by product segment, 2017 to 2023 (central nervous system, dermatological, gastrointestinal, respiratory, other, total). The coverage of regional OTC markets in the report goes to the country level in North America, Asia Pacific, Europe, Latin America, and Middle East and Africa.

Kalorama Information divides and discusses OTC product markets in five general segments: OTC central nervous system agents (analgesics, anti-inflammatories, and other central nervous system agents), OTC dermatological agents (acne treatments, antifungals/antiinfectives, hair growth remedies, others), OTC gastrointestinal system agents (laxatives, antacids, antidiarrheals, H2 antagonists, proton pump inhibitors), OTC respiratory system agents (antihistamines, decongestants, cough preparations, other respiratory agents), and OTC agents – various therapeutic classifications (smoking cessation market, contraceptive drugs, weight management drugs [OTC drugs, not dietary supplements], overactive bladder treatments).

Global OTC Drug Markets notes the leading suppliers’ shares of the OTC drug market by revenues for 2017 and also includes in-depth profiles of market competitors such as Bayer, Johnson & Johnson, Pfizer, Procter & Gamble, and Sanofi.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

BACKGROUND

SCOPE AND METHODOLOGY

SIZE AND GROWTH OF THE GLOBAL OTC MARKET

Figure 1-1: Global Over-the-Counter Drug Market Analysis: 2017 to 2023 (millions USD)

Global Markets

Figure 1-2: Top Twenty OTC Drug Markets, Country Market Share (%), 2017 (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia, Rest of World)

Leading Competitors

CHAPTER TWO: INTRODUCTION

BACKGROUND

DISTRIBUTION AND SAFETY ISSUES IN THE UNITED STATES

CONSUMER ADVERTISING AND PROMOTION

GLOBAL HEALTH

Global Life Expectancy

Table 2-1: Average Life Expectancy in Years by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela, Global Average)

Figure 2-1: Average Life Expectancy in Years by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)

Global Trends in Birth Rates

Table 2-2: Crude Birth Rate per 1,000 Persons by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela, Global Average)

Figure 2-2: Crude Birth Rate per 1,000 Persons by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)

Tobacco Use

Figure 2-3: Percent of Tobacco Users as a Percentage of Population by Country, 1990 vs. 2010 (%) (Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, South Africa, Spain, Turkey, United Kingdom, United States)

Obesity

Figure 2-4: Obesity Prevalence as a Percentage of Population by Country, 2006 vs. 2016 (%) (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)

Declining Growth of the Global Population

Table 2-3: Global Population 1980 to 2050 (millions)

Figure 2-5: The Global Population, 1980-2050

Figure 2-6: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

PRESCRIPTION VS. OVER-THE-COUNTER INDUSTRY

Figure 2-7: Total Pharmaceutical Markets: Prescription vs. Non-Prescription by Country, 2017 (% of total pharmaceutical market) (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia)

OVER-THE-COUNTER DRUG PRODUCT SEGMENTS

Table 2-4: Global OTC Drug Market Analysis, Markets by Product Segment, 2017 to 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)

Figure 2-8: Global OTC Drug Market Analysis, Markets by Product Segment, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

RX-TO-OTC SWITCH INDUSTRY

Table 2-5: Leading FDA approved Rx-to-OTC switches, 1994-2017

Figure 2-9: Number of New Rx-to-OTC Switches in the United States, per year 1976-2017

ECONOMIC TRENDS

Figure 2-10: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, 2010 and 2020 Estimated (%) (United States, France, Germany, Canada, Japan, United Kingdom, Australia, Italy, Spain, South Africa, Brazil, Russia, Mexico, Poland, China, Venezuela, Turkey, India, Argentina, Saudi Arabia)

Purchasing Power Trends

Figure 2-11: Gross National Income by Country 1990-2010 and Estimated 2020 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)

HEALTH INSURANCE ISSUES AND TRENDS: UNITED STATES

Figure 2-12: Number of Insured vs. Uninsured in the United States 2005-2016

Figure 2-13: Number of Insured Children vs. Uninsured Children in the United States 2005-2016

Figure 2-14: Number of Insured Children vs. Uninsured Children in the United States 2005-2016

CONSUMER ISSUES AND TRENDS

Access to Professional Medical Services and the Link to Self-Medication

Figure 2-15: Practicing Physicians per 1,000 Population by Country, 2017 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)

REGULATORY SOLUTIONS TO OTC DRUG ACCESS

Revisions to Pharmaceutical Affairs Law (PAL) in Japan

Figure 2-16: Typical Pharmacist-Consumer OTC Drug Counseling Session

Changes to Australia’s OTC Drug Access – Up-scheduling Combination Medicines Containing  

Codeine

Figure 2-17: National Classification System of Scheduling Medicines

CHAPTER THREE: OVER-THE-COUNTER CENTRAL NERVOUS SYSTEM AGENTS

MARKET SUMMARY

Figure 3-1: Global OTC Central Nervous System Agent Market, 2017-2023

MARKET BY DRUG SEGMENT

Figure 3-2: Global OTC Central Nervous System Agent Market, Distribution of Sales by Drug Segment 2017 (%)

MARKETS BY REGION

Asia Pacific

Figure 3-3: Asia Pacific OTC Central Nervous System Agent Market, 2017-2023 ($ millions)

Europe

Figure 3-4: Europe OTC Central Nervous System Agent Market, 2017-2023 ($ millions)

Latin America

Figure 3-5: Latin America OTC Central Nervous System Agent Market, 2017-2023 ($ millions)

Middle East & Africa

Figure 3-6: Middle East & Africa OTC Central Nervous System Agent Market, 2017-2023 ($ millions)

North America

Figure 3-7: North America OTC Central Nervous System Agent Market, 2017-2023 ($ millions)

CHAPTER FOUR: OVER-THE-COUNTER DERMATOLOGICAL AGENTS

MARKET SUMMARY

Figure 4-1: Global OTC Dermatological Agent Market, 2017-2023

MARKET BY DRUG SEGMENT

Figure 4-2: Global OTC Dermatological Agent Market, Distribution of Sales by Drug Segment 2017 (%) (Acne

Treatments, Antifungals/Antiinfectives, Hair Growth Remedies, Others)

MARKETS BY REGION

Asia Pacific

Figure 4-3: Asia Pacific OTC Dermatological Agent Market, 2017-2023 ($ millions)

Europe

Figure 4-4: Europe OTC Dermatological Agent Market, 2017-2023 ($ millions)

Latin America

Figure 4-5: Latin America OTC Dermatological Agent Market, 2017-2023 ($ millions)

Middle East & Africa

Figure 4-6: Middle East & Africa OTC Dermatological Agent Market, 2017-2023 ($ millions)

North America

Figure 4-7: North America OTC Dermatological Agent Market, 2017-2023 ($ millions)

CHAPTER FIVE: OVER-THE-COUNTER GASTROINTESTINAL SYSTEM AGENTS

MARKET SUMMARY

Figure 5-1: Global OTC Gastrointestinal Agent Market, 2017-2023

MARKET BY DRUG SEGMENT

Figure 5-2: Global Gastrointestinal OTC Market, Distribution of Sales by Drug Segment 2017 (%) (Laxatives, Antacids, Antidiarrheals, H2 Antagonists, Proton Pump Inhibitors)

MARKETS BY REGION

Asia Pacific

Figure 5-3: Asia Pacific OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)

Europe

Figure 5-4: Europe OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)

Latin America

Figure 5-5: Latin America OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)

Middle East & Africa

Figure 5-6: Middle East & Africa OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)

North America

Figure 5-7: North America OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)

CHAPTER SIX: OVER-THE-COUNTER RESPIRATORY SYSTEM AGENTS

MARKET SUMMARY

Figure 6-1: Global OTC Respiratory Agent Market, 2017-2023

MARKET BY DRUG SEGMENT

Figure 6-2: Global OTC Respiratory Agent Market, Distribution of Sales by Drug Segment 2017 (%) (Antihistamines, Decongestants, Cough Preparations, Other Respiratory Agents)

Table 6-1: Global OTC Respiratory Agent Market, Sales by Indication, 2017-2023 ($ in millions) (Allergy/Asthma, Cough/Cold, Total)

Figure 6-3: Global OTC Respiratory Agent Market, Distribution of Sales by Indication 2017 (%) (Allergy/Asthma, Cough/Cold)

MARKETS BY REGION

Asia Pacific

Figure 6-4: Asia Pacific OTC Respiratory Agent Market, 2017-2023 ($ millions)

Europe

Figure 6-5: Europe OTC Respiratory Agent Market, 2017-2023 ($ millions)

Latin America

Figure 6-6: Latin America OTC Respiratory Agent Market, 2017-2023 ($ millions)

Middle East & Africa

Figure 6-7: Middle East & Africa OTC Respiratory Agent Market, 2017-2023 ($ millions)

North America

Figure 6-8: North America OTC Respiratory Agent Market, 2017-2023 ($ millions)

CHAPTER SEVEN: OVER-THE-COUNTER AGENTS VARIOUS THERAPEUTIC CLASSIFICATIONS

MARKET SUMMARY

Figure 7-1: Global OTC Other Therapies Market, 2017-2023

MARKETS BY REGION

Asia Pacific

Figure 7-2: Asia Pacific OTC Other Therapies Market, 2017-2023 ($ millions)

Europe

Figure 7-3: Europe OTC Other Therapies Market, 2017-2023 ($ millions)

Latin America

Figure 7-4: Latin America OTC Other Therapies Market, 2017-2023 ($ millions)

Middle East & Africa

Figure 7-5: Middle East & Africa OTC Other Therapies Market, 2017-2023 ($ millions)

North America

Figure 7-6: North America OTC Other Therapies Market, 2017-2023 ($ millions)

CHAPTER EIGHT: OTC DRUG MARKETS IN ASIA PACIFIC

REGIONAL OVERVIEW

Table 8-1: Asia Pacific Select Countries, Demographic Profile, 2017 and 2030 (Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Vietnam)

Figure 8-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Vietnam)

OTC DRUG SALES AND GROWTH IN ASIA PACIFIC MARKETS

Figure 8-2: OTC Drug Market in Asia Pacific Region, 2017-2023 (in millions of dollars at the manufacturers’ level)

Sales for OTC Drug Markets by Country

Figure 8-3: Asia Pacific OTC Drug Market Value by Country, 2017 and 2023 (Australia, China, India, Japan, Rest of Asia Pacific)

Figure 8-4: Asia Pacific OTC Drug Markets by Country, 2017 (%) (Australia, China, India, Japan, Rest of Asia Pacific)

Figure 8-5: OTC Drug Markets in Japan by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Figure 8-6: OTC Drug Markets in China by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Figure 8-7: OTC Drug Markets in India by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Figure 8-8: OTC Drug Markets in Australia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

ASIA PACIFIC OTC MARKETS BY THERAPEUTIC CLASS

Table 8-2: Asia-Pacific OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)

Figure 8-9: Asia-Pacific OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER NINE: OTC DRUG MARKETS IN EUROPE

REGIONAL OVERVIEW

Table 9-1: Europe Select Countries, Demographic Profile, 2017 and 2030 (France, Germany, Italy, Poland, Russia, Spain, Sweden, Switzerland, Turkey, United Kingdom)

Figure 9-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (France, Germany, Italy, Poland, Russia, Spain, Sweden, Switzerland, Turkey, United Kingdom)

OTC DRUG SALES AND GROWTH IN EUROPE MARKETS

Figure 9-2: OTC Drug Market in Europe Region, 2017-2023 (in millions of dollars at the manufacturers’ level)

SALES FOR OTC DRUG MARKETS BY EUROPEAN COUNTRY

Figure 9-3: Europe OTC Drug Market Value by Country, 2017 and 2023 (France, Germany, Italy, Poland, Russia, Spain, Turkey, United Kingdom)

Figure 9-4: Europe OTC Drug Markets by Country, 2017 (%) (France, Germany, Italy, Poland, Russia, Spain, Turkey, United Kingdom, Rest of Europe)

Germany

Figure 9-5: OTC Drug Markets in Germany by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

France

Figure 9-6: OTC Drug Markets in France by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Russia

Figure 9-7: OTC Drug Markets In Russia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

United Kingdom

Figure 9-8: OTC Drug Markets in The United Kingdom by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Italy

Figure 9-9: OTC Drug Markets in Italy by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Spain

Figure 9-10: OTC Drug Markets in Spain by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Poland

Figure 9-11: OTC Drug Markets in Poland by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Turkey

Figure 9-12: OTC Drug Markets in Turkey by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

EUROPE OTC MARKETS BY THERAPEUTIC CLASS

Table 9-2: Europe OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)

Figure 9-13: Europe OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER TEN: OTC DRUG MARKETS IN LATIN AMERICA

REGIONAL OVERVIEW

Table 10-1: Latin America Select Countries, Demographic Profile, 2017 and 2030 (Argentina, Brazil, Chile, Mexico, Venezuela)

Figure 10-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Argentina, Brazil, Chile, Mexico, Venezuela)

OTC DRUG SALES AND GROWTH IN LATIN AMERICA MARKETS

Table 10-2: OTC Drug Market in Latin America Region, 2017-2023 (in millions of dollars at the manufacturers’ level)

SALES FOR OTC DRUG MARKETS BY COUNTRY

Figure 10-2: Latin America OTC Drug Market Value by Country, 2017 and 2023 (Argentina, Brazil, Mexico, Venezuela, Rest of Latin America)

Figure 10-3: Latin America OTC Drug Markets by Country, 2017 (%) (Argentina, Brazil, Mexico, Venezuela, Rest of Latin America)

Brazil

Figure 10-4: OTC Drug Markets in Brazil by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Mexico

Figure 10-5: OTC Drug Markets in Mexico by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Argentina

Figure 10-6: OTC Drug Markets in Argentina by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Venezuela

Figure 10-7: OTC Drug Markets in Venezuela by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

LATIN AMERICA OTC MARKETS BY THERAPEUTIC CLASS

Table 10-3: Latin America OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)

Figure 10-8: Latin America OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER ELEVEN: OTC DRUG MARKETS IN MIDDLE EAST & AFRICA

REGIONAL OVERVIEW

Table 11-1: Middle East & Africa Select Countries, Demographic Profile, 2017 and 2030 (Egypt, Iran, Israel, Saudi Arabia, South Africa, UAE)

Figure 11-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Egypt, Iran, Israel, Saudi Arabia, South Africa, UAE)

OTC DRUG SALES AND GROWTH IN MIDDLE EAST & AFRICA MARKETS

Figure 11-2: OTC Drug Market in Middle East & Africa Region, 2017-2023 (in millions of dollars at the manufacturers’ level)

SALES FOR OTC DRUG MARKETS BY COUNTRY

Figure 11-3: Middle East & Africa OTC Drug Market Value by Country, 2017 and 2023 (Saudi Arabia, South Africa, Rest of Middle East & Africa)

Figure 11-4: OTC Drug Markets by Country, 2017 (%) (Saudi Arabia, South Africa, Rest of Middle East & Africa)

South Africa

Figure 11-5: OTC Drug Markets in South Africa by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Saudi Arabia

Figure 11-6: OTC Drug Markets in Saudi Arabia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

MIDDLE EAST & AFRICA OTC MARKETS BY THERAPEUTIC CLASS

Table 11-2: Middle East & Africa OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)

Figure 11-7: Middle East & Africa OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER TWELVE: OTC DRUG MARKETS IN NORTH AMERICA

REGIONAL OVERVIEW

Table 12-1: North America Select Countries, Demographic Profile, 2017 and 2030 (Canada, United States)

Figure 12-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Canada, United States)

OTC DRUG SALES AND GROWTH IN NORTH AMERICA MARKETS

Figure 12-2: OTC Drug Markets in North America Region, 2017-2023 (in millions of dollars at the manufacturers’ level)

Sales for OTC Drug Markets by Country

Figure 12-3: North America OTC Drug Market Value by Country, 2017 and 2023 (Canada, United States, Rest of North America)

Figure 12-4: North America OTC Drug Markets by Country, 2017 (%) (Canada, United States, Rest of North America)

United States

Figure 12-5: OTC Drug Markets in the United States by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

Canada

Figure 12-6: OTC Drug Markets in Canada by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

NORTH AMERICA OTC MARKETS BY THERAPEUTIC CLASS

Table 12-2: North America OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)

Figure 12-7: North America OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER THIRTEEN: LEADING OTC DRUG MANUFACTURERS

OVERVIEW

COMPETITOR ANALYSIS

Table 13-1: Leading Suppliers Shares of the OTC Drug Market by Revenues—2017

Figure 13-1: Leading Suppliers Shares of the OTC Drug Market, 2017

A DECADE OF AGREEMENTS, MERGERS AND ACQUISITIONS SHAPING THE OTC DRUG MARKET

Sanofi and Boehringer Ingelheim

GlaxoSmithKline and Novartis AG

Bayer AG and Merck & Co.

Prestige Brands and Insight Pharmaceuticals

Perrigo Company Acquisitions

Procter & Gamble and Teva Pharmaceutical Industries

Sanofi and Chattem Consumer

Wyeth and Pfizer

Reckitt Benckiser and Adams Respiratory Therapeutics

LEADING CORPORATE PROFILES

Bayer AG

Table 13-2: Bayer Corporate Summary

Table 13-3: Bayer Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December) .. 153

GlaxoSmithKline plc

Table 13-4: GlaxoSmithKline Corporate Summary

Table 13-5: GlaxoSmithKline Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)

Johnson & Johnson

Table 13-6: Johnson & Johnson Corporate Summary

Table 13-7: Johnson & Johnson Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)

Mylan N.V.

Table 13-8: Mylan Corporate Summary

Table 13-9: Mylan Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)

Perrigo Company plc

Table 13-10: Perrigo Company Corporate Summary

Table 13-11: Perrigo Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)

Pfizer, Inc.

Table 13-12: Pfizer Corporate Summary

Table 13-13: Pfizer Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)

Procter & Gamble Company

Table 13-14: Procter & Gamble Company Corporate Summary

Table 13-15: Procter & Gamble Recent Revenue History, 2015-2017 (US$ Millions, financial year ending June)

Reckitt Benckiser Group Plc

Table 13-16: Reckitt Benckiser Group Corporate Summary

Table 13-17: Reckitt Benckiser Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)

Sanofi

Table 13-18: Sanofi Corporate Summary

Table 13-19: Sanofi Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)

Taisho Pharmaceutical Holding Co., Ltd.

Table 13-20: Taisho Pharmaceutical Holding Corporate Summary

Table 13-21: Taisho Pharmaceutical Recent Revenue History, FY End 2016-2017 (US$ Millions, financial year ending March)

 

    The Market for Rx-to-OTC Switches, 8th Edition
    May 5, 2022
    Global Over-the-Counter (OTC) Drug Markets
    January 23, 2018
    The US Market for Rx to OTC Switches, Forecasts to 2019, 7th Edition
    February 2, 2015
    The U.S. Market for Rx to OTC Switches, 6th Edition
    January 11, 2013

Related products

  • Placeholder image

    Women’s Health: Worldwide Prescription Drug Markets – 3rd Edition

    $2,812.00 – $5,625.00
  • Placeholder image

    U.S. Market for OTC Diet Aids, The

    $3,000.00 – $6,000.00
  • Placeholder image

    Growth Factors: Indications, Products, and Markets

    $2,625.00 – $5,250.00
  • Placeholder image

    World Market for Anti-infectives Series: Volumes I – III – Antifungals, Antibacterials and Antivirals, The

    $6,000.00 – $12,000.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain  June 24, 2025
  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Direct-to-Consumer Testing MarketThe Market and Potential for Molecular Point of Care Diagnostic Tests
Scroll to top